OLŠOVSKÝ, Jindřich. Komentář ke studii LEADER (Commentary on the LEADER study). In Milan Kvapil. Diabetologie 2017. 1st ed. Praha: Triton, 2017, p. 225-229. ISBN 978-80-7553-262-6.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Komentář ke studii LEADER
Name (in English) Commentary on the LEADER study
Authors OLŠOVSKÝ, Jindřich (203 Czech Republic, guarantor, belonging to the institution).
Edition 1. vyd. Praha, Diabetologie 2017, p. 225-229, 5 pp. 2017.
Publisher Triton
Other information
Original language Czech
Type of outcome Proceedings paper
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Publication form printed version "print"
RIV identification code RIV/00216224:14110/17:00096526
Organization unit Faculty of Medicine
ISBN 978-80-7553-262-6
Keywords (in Czech) diabetes mellitus; kardiovaskulární bezpečnost
Keywords in English diabetes mellitus; cardiovascular safety
Tags EL OK
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 1/8/2017 16:47.
Abstract
Studie LEADER sleduje kardiovaskulární bezpečnost liraglutidu u pacientů s diabetes mellitus a kardiovaskulárním onemocněním či s rizikem jeho vzniku. Prokázala jak účinnost, tak bezpečnost podání liraglutidu, včetně snížení celkové mortality pacientů.
Abstract (in English)
LEADER study investigates cardiovascular safety of liraglutide in patients with diabetes mellitus, and cardiovascular disease or at risk thereof. Study has proved the drug efficacy as well as the safety of its administration, including reduction of all-cause mortality.
PrintDisplayed: 26/4/2024 10:20